Syneos Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michelle Keefe
- Full Time Employees
- 28,768
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 1030 Sync Street Morrisville NC United States of America 27560-5468
- IPO Date
- Nov 7, 2014
- CIK
- 0001610950
- Website
- syneoshealth.com
- Similar Companies
- Business
- Syneos Health, Inc. (SYNH) operates as a fully integrated biopharmaceutical solutions organization that provides contract research organization (CRO) services and commercialization support to pharmaceutical, biotechnology, and medical device companies worldwide. The company offers clinical solutions encompassing Phase I to IV clinical trials, including regulatory consulting, project management, protocol development, site recruitment and monitoring, patient recruitment and engagement, biometrics, real-world evidence, clinical pharmacology, bioanalytical services, pharmacovigilance, and functional service partnerships (FSP); commercial solutions including deployment and field-based promotional services, market access, communications such as public relations and advertising, medical affairs, consulting, predictive analytics, and patient support programs. Syneos Health maintains deep therapeutic expertise in areas such as oncology (supporting 96% of novel FDA-approved oncology drugs and 93% of EMA-authorized products over the last five years), hematology, central nervous system disorders, and general medicine, with operations spanning more than 110 countries across North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. Founded in 2018 through the merger of INC Research and InVentiv Health (with roots tracing to the 1980s via predecessor entities), the company is headquartered in Morrisville, North Carolina, and employs approximately 28,000 people. In recent developments, Syneos Health was taken private in September 2023 by a consortium of Elliott Investment Management, Patient Square Capital, and Veritas Capital in a transaction valued at approximately $7.1 billion including debt; sold its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners in June 2024 to streamline operations; partnered with CareMetx in 2025 to enhance patient access solutions; collaborated with Microsoft on AI-driven clinical trial optimization since 2023; and appointed Costa Panagos as CEO in October 2024.
Syneos Health Appoints Greg Licholai as Chief Medical Officer to Advance Next-Generation Drug Development
causaLens Expands Strategic Partnership with Syneos Health to Scale Agentic AI in Biopharma Commercialization
KAI Conversations Announces Strategic Partnership with Syneos Health to Advance U.S. Pharmaceutical Commercialization
Syneos Health Appoints Simon Bartle as Chief Human Resources Officer
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
Syneos Health Appoints Costa Panagos as Chief Executive Officer
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health
Syneos Health Closes Transaction with Private Investment Firms
Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Syneos Health, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 25, 2023 - (NASDAQ: SYNH)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc. (SYNH)
Attention SYNH Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Syneos Health, Inc. (SYNH) and Encourages Investors to Contact the Firm
SYNH Investors Have Opportunity to Lead Syneos Health, Inc. Securities Fraud Lawsuit
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syneos Health, Inc. - SYNH
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Syneos Health, Inc.(SYNH) Investors of a Class Action Lawsuit and Upcoming Deadline